Imagine a world where a simple test could unlock the key to a child's future, a world where early detection is not just a luxury but a necessity. This is the story of universal screening for congenital cytomegalovirus (cCMV), a silent threat that can rob newborns of their hearing. But here's where it gets controversial: should we implement universal screening for cCMV, and what impact could it have on our healthcare systems and families? Let's dive in.
The Critical Impact of Early Detection
A groundbreaking study, published in the November 2025 issue of Otolaryngology–Head and Neck Surgery, has revealed the profound impact of cCMV infection on hearing outcomes. The research, conducted over eight years, examined the audiological outcomes of newborns screened for cCMV through universal screening programs. The findings are eye-opening: approximately one-third of cCMV-related hearing loss develops after the newborn period, cases that would have gone unnoticed without universal screening.
Congenital cytomegalovirus is the most common non-genetic cause of sensorineural hearing loss (SNHL) in children, and it can affect even asymptomatic infants. Maria A. Carrillo-Marquez, MD, an associate professor at The University of Tennessee Health Science Center, emphasizes the importance of universal screening: "Our study highlights the need for early identification of infants at risk for sensorineural hearing loss. Universal screening is the key to catching these cases before they progress."
The study analyzed data from 247 cCMV-positive newborns in Memphis, Tennessee. Among them, 24 infants (around 10%) were diagnosed with SNHL. Sixteen of these cases were identified during the neonatal period, but eight developed late-onset hearing loss between 6 and 12 months of age. Shockingly, five of these late-onset cases occurred in infants who showed no symptoms at birth.
Connecting Research to Policy: A National Priority
The implications of this research are far-reaching. With one in 200 infants born with congenital cytomegalovirus, and one in five developing long-term complications like hearing loss, seizures, and developmental delays, the need for comprehensive screening programs is urgent. The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) has made cCMV screening a top legislative priority, advocating for federal and state-level legislation to implement universal newborn cCMV screening.
Rahul K. Shah, MD, MBA, AAO-HNS/F Executive Vice President and CEO, emphasizes the importance of translating research into action: "The evidence is clear: universal screening is crucial. As specialists in hearing health, we understand the critical role of screening in facilitating timely intervention. Early diagnosis and treatment of cCMV-related neurodevelopmental issues are essential for the long-term success of our children."
Federal and State-Level Advocacy
The Stop CMV Act (H.R. 5435/S. 2842) was reintroduced in the 119th Congress, thanks to the efforts of AAO-HNS and its allies. This legislation aims to authorize federal funding for cCMV screening programs, improving early detection and intervention for hearing loss in infants. At the state level, the Academy's advocacy efforts are gaining momentum:
- Oregon: The Oregon Legislature unanimously passed HB 2685, expanding targeted screening for cCMV. The law ensures testing for newborns who fail initial hearing screenings, with insurance coverage for these tests. AAO-HNS supported this legislation, recognizing the importance of early detection.
- New York: The Academy is advocating for A.3956 and S.5454, bills that would establish universal cCMV screening. A.3956 offers flexibility with dried blood spot or urine PCR tests, while S.5454 mandates urine PCR only. The Academy encourages alignment with the Assembly version for practical implementation.
- Massachusetts: The Academy submitted testimony in support of H. 4367, which requires universal cCMV screening, a public education program, and an advisory committee. Early detection within the first 21 days is crucial for timely interventions, including antiviral therapy and developmental support.
- Looking Ahead: Several states, including Michigan, Texas, and Wisconsin, are expected to propose cCMV screening soon.
Key Study Findings: A Snapshot
The Memphis study found that cCMV affected 0.5% of screened newborns, consistent with national estimates. Here are some key findings:
- Approximately 10% of cCMV-positive infants developed SNHL.
- Half of all hearing loss cases were bilateral, while the other half were unilateral.
- Symptomatic infants had higher rates of microcephaly and intracranial calcifications.
- Nine patients received cochlear implants, and four have hearing aids.
- Social vulnerability impacted follow-up visits, highlighting the role of social determinants of health.
The study also revealed challenges with patient follow-up, particularly for families facing socioeconomic barriers. Of the original 247 patients, 137 (55%) were lost to follow-up between one and three months, mostly from families with higher social vulnerability scores. This emphasizes the need for comprehensive support systems alongside screening programs.
A Progressive Threat: The Silent Impact of cCMV
Congenital cytomegalovirus is the leading infectious cause of birth defects and the top non-genetic cause of hearing loss in infants. CMV-related hearing loss can be progressive, with about 50% of affected children experiencing worsening over time. The hallmark of cCMV is progressive and permanent hearing loss, which can present at birth or later in life. Universal screening is essential to identify all at-risk infants, not just those with symptoms.
For more information, visit the Academy's position statement on cCMV screening and the Stop CMV Act. Otolaryngology–Head and Neck Surgery is dedicated to publishing ethical, clinically relevant information to improve patient care and public health.
Conclusion: A Call to Action
The study's findings underscore the critical role of universal screening for cCMV in identifying infants at risk for hearing loss. As we navigate the complex landscape of healthcare policy, the question remains: will we prioritize early detection and intervention for our most vulnerable population? The impact of our decisions today could shape the future of countless children.
What are your thoughts on universal screening for cCMV? Do you think it should be a national priority? Share your opinions in the comments below!
